Prostate Trials
KEYNOTE-991 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). |
KEYNOTE-991 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). |
MON | 7:30am - 5:00pm |
TUE | 7:30am - 5:00pm |
WED | 7:30am - 5:00pm |
THU | 7:30am - 5:00pm |
FRI | 7:30am - 5:00pm |
SAT | closed |
SUN | closed |
After Hours Emergency: Please access your local hospital emergency department.